SABRA HEALTH CARE REIT INC (SBRA) Fundamental Analysis & Valuation

NASDAQ:SBRA • US78573L1061

Current stock price

20.045 USD
-0.45 (-2.22%)
Last:

This SBRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. SBRA Profitability Analysis

1.1 Basic Checks

  • SBRA had positive earnings in the past year.
  • SBRA had a positive operating cash flow in the past year.
  • In multiple years SBRA reported negative net income over the last 5 years.
  • SBRA had a positive operating cash flow in each of the past 5 years.
SBRA Yearly Net Income VS EBIT VS OCF VS FCFSBRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 2.83%, SBRA is in the better half of the industry, outperforming 72.95% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 5.51%, SBRA is in the better half of the industry, outperforming 68.03% of the companies in the same industry.
  • SBRA has a better Return On Invested Capital (3.88%) than 72.13% of its industry peers.
  • SBRA had an Average Return On Invested Capital over the past 3 years of 3.71%. This is in line with the industry average of 3.12%.
  • The last Return On Invested Capital (3.88%) for SBRA is above the 3 year average (3.71%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.83%
ROE 5.51%
ROIC 3.88%
ROA(3y)1.83%
ROA(5y)0.45%
ROE(3y)3.54%
ROE(5y)0.95%
ROIC(3y)3.71%
ROIC(5y)3.47%
SBRA Yearly ROA, ROE, ROICSBRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • SBRA has a better Profit Margin (20.09%) than 72.95% of its industry peers.
  • In the last couple of years the Profit Margin of SBRA has declined.
  • The Operating Margin of SBRA (34.06%) is better than 70.49% of its industry peers.
  • SBRA's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 66.87%, SBRA is in line with its industry, outperforming 47.54% of the companies in the same industry.
  • SBRA's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 34.06%
PM (TTM) 20.09%
GM 66.87%
OM growth 3Y-3.2%
OM growth 5Y-4.77%
PM growth 3YN/A
PM growth 5Y-2.77%
GM growth 3Y-4.64%
GM growth 5Y-4.04%
SBRA Yearly Profit, Operating, Gross MarginsSBRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. SBRA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SBRA is destroying value.
  • Compared to 1 year ago, SBRA has more shares outstanding
  • SBRA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, SBRA has a worse debt to assets ratio.
SBRA Yearly Shares OutstandingSBRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
SBRA Yearly Total Debt VS Total AssetsSBRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • Based on the Altman-Z score of 0.96, we must say that SBRA is in the distress zone and has some risk of bankruptcy.
  • SBRA's Altman-Z score of 0.96 is fine compared to the rest of the industry. SBRA outperforms 71.31% of its industry peers.
  • A Debt/Equity ratio of 0.90 indicates that SBRA is somewhat dependend on debt financing.
  • SBRA has a better Debt to Equity ratio (0.90) than 63.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 0.96
ROIC/WACC0.54
WACC7.17%
SBRA Yearly LT Debt VS Equity VS FCFSBRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.48 indicates that SBRA should not have too much problems paying its short term obligations.
  • With a decent Current ratio value of 1.48, SBRA is doing good in the industry, outperforming 72.13% of the companies in the same industry.
  • A Quick Ratio of 1.48 indicates that SBRA should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.48, SBRA is in the better half of the industry, outperforming 73.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.48
SBRA Yearly Current Assets VS Current LiabilitesSBRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SBRA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.75% over the past year.
  • The Earnings Per Share has been decreasing by -0.91% on average over the past years.
  • The Revenue has grown by 10.15% in the past year. This is quite good.
  • Measured over the past years, SBRA shows a small growth in Revenue. The Revenue has been growing by 5.29% on average per year.
EPS 1Y (TTM)20.75%
EPS 3YN/A
EPS 5Y-0.91%
EPS Q2Q%-42.11%
Revenue 1Y (TTM)10.15%
Revenue growth 3Y7.43%
Revenue growth 5Y5.29%
Sales Q2Q%16.21%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.11% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 11.91% on average over the next years. This is quite good.
EPS Next Y15.21%
EPS Next 2Y10.92%
EPS Next 3Y9.11%
EPS Next 5YN/A
Revenue Next Year11.84%
Revenue Next 2Y10.45%
Revenue Next 3Y9.97%
Revenue Next 5Y11.91%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SBRA Yearly Revenue VS EstimatesSBRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
SBRA Yearly EPS VS EstimatesSBRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. SBRA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 31.32 indicates a quite expensive valuation of SBRA.
  • Based on the Price/Earnings ratio, SBRA is valued a bit cheaper than the industry average as 67.21% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.95, SBRA is valued at the same level.
  • A Price/Forward Earnings ratio of 27.19 indicates a quite expensive valuation of SBRA.
  • Based on the Price/Forward Earnings ratio, SBRA is valued cheaply inside the industry as 83.61% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 38.68, SBRA is valued a bit cheaper.
Industry RankSector Rank
PE 31.32
Fwd PE 27.19
SBRA Price Earnings VS Forward Price EarningsSBRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SBRA is valued a bit more expensive than 62.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.92
SBRA Per share dataSBRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2.06
PEG (5Y)N/A
EPS Next 2Y10.92%
EPS Next 3Y9.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. SBRA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 5.81%, SBRA is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 7.46, SBRA pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.81, SBRA pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.81%

5.2 History

  • The dividend of SBRA decreases each year by -2.44%.
  • SBRA has paid a dividend for at least 10 years, which is a reliable track record.
  • SBRA has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-2.44%
Div Incr Years0
Div Non Decr Years2
SBRA Yearly Dividends per shareSBRA Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5

5.3 Sustainability

  • SBRA pays out 186.04% of its income as dividend. This is not a sustainable payout ratio.
DP186.04%
EPS Next 2Y10.92%
EPS Next 3Y9.11%
SBRA Yearly Income VS Free CF VS DividendSBRA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M
SBRA Dividend Payout.SBRA Dividend Payout, showing the Payout Ratio.SBRA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

SBRA Fundamentals: All Metrics, Ratios and Statistics

SABRA HEALTH CARE REIT INC

NASDAQ:SBRA (4/21/2026, 3:50:01 PM)

20.045

-0.45 (-2.22%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners105.32%
Inst Owner Change-0.01%
Ins Owners1.1%
Ins Owner Change6.47%
Market Cap5.05B
Revenue(TTM)774.63M
Net Income(TTM)155.61M
Analysts76
Price Target22.28 (11.15%)
Short Float %11.15%
Short Ratio10.45
Dividend
Industry RankSector Rank
Dividend Yield 5.81%
Yearly Dividend1.18
Dividend Growth(5Y)-2.44%
DP186.04%
Div Incr Years0
Div Non Decr Years2
Ex-Date02-13
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-44.68%
Min EPS beat(2)-51.75%
Max EPS beat(2)-37.61%
EPS beat(4)1
Avg EPS beat(4)-10.49%
Min EPS beat(4)-51.75%
Max EPS beat(4)51.26%
EPS beat(8)2
Avg EPS beat(8)-12.84%
EPS beat(12)2
Avg EPS beat(12)-37.62%
EPS beat(16)3
Avg EPS beat(16)-70.46%
Revenue beat(2)1
Avg Revenue beat(2)6.1%
Min Revenue beat(2)-0.25%
Max Revenue beat(2)12.46%
Revenue beat(4)3
Avg Revenue beat(4)3.96%
Min Revenue beat(4)-0.25%
Max Revenue beat(4)12.46%
Revenue beat(8)7
Avg Revenue beat(8)2.98%
Revenue beat(12)8
Avg Revenue beat(12)2%
Revenue beat(16)10
Avg Revenue beat(16)1.09%
PT rev (1m)1.43%
PT rev (3m)4.8%
EPS NQ rev (1m)-1.1%
EPS NQ rev (3m)-5.81%
EPS NY rev (1m)-3.62%
EPS NY rev (3m)-6.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.23%
Valuation
Industry RankSector Rank
PE 31.32
Fwd PE 27.19
P/S 6.52
P/FCF N/A
P/OCF 14.5
P/B 1.79
P/tB 1.83
EV/EBITDA 16.92
EPS(TTM)0.64
EY3.19%
EPS(NY)0.74
Fwd EY3.68%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)1.38
OCFY6.9%
SpS3.07
BVpS11.19
TBVpS10.93
PEG (NY)2.06
PEG (5Y)N/A
Graham Number12.6946 (-36.67%)
Profitability
Industry RankSector Rank
ROA 2.83%
ROE 5.51%
ROCE 4.91%
ROIC 3.88%
ROICexc 3.93%
ROICexgc 3.98%
OM 34.06%
PM (TTM) 20.09%
GM 66.87%
FCFM N/A
ROA(3y)1.83%
ROA(5y)0.45%
ROE(3y)3.54%
ROE(5y)0.95%
ROIC(3y)3.71%
ROIC(5y)3.47%
ROICexc(3y)3.75%
ROICexc(5y)3.51%
ROICexgc(3y)3.78%
ROICexgc(5y)3.54%
ROCE(3y)4.7%
ROCE(5y)4.39%
ROICexgc growth 3Y5.81%
ROICexgc growth 5Y1.97%
ROICexc growth 3Y5.63%
ROICexc growth 5Y2.01%
OM growth 3Y-3.2%
OM growth 5Y-4.77%
PM growth 3YN/A
PM growth 5Y-2.77%
GM growth 3Y-4.64%
GM growth 5Y-4.04%
F-Score5
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA 5.61
Cap/Depr 242.22%
Cap/Sales 58.47%
Interest Coverage 2.38
Cash Conversion 77.32%
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.48
Altman-Z 0.96
F-Score5
WACC7.17%
ROIC/WACC0.54
Cap/Depr(3y)121.85%
Cap/Depr(5y)94.04%
Cap/Sales(3y)30%
Cap/Sales(5y)24.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.75%
EPS 3YN/A
EPS 5Y-0.91%
EPS Q2Q%-42.11%
EPS Next Y15.21%
EPS Next 2Y10.92%
EPS Next 3Y9.11%
EPS Next 5YN/A
Revenue 1Y (TTM)10.15%
Revenue growth 3Y7.43%
Revenue growth 5Y5.29%
Sales Q2Q%16.21%
Revenue Next Year11.84%
Revenue Next 2Y10.45%
Revenue Next 3Y9.97%
Revenue Next 5Y11.91%
EBIT growth 1Y2.66%
EBIT growth 3Y4%
EBIT growth 5Y0.26%
EBIT Next Year84.43%
EBIT Next 3Y26.83%
EBIT Next 5Y18.61%
FCF growth 1Y-159.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.26%
OCF growth 3Y3.36%
OCF growth 5Y-0.36%

SABRA HEALTH CARE REIT INC / SBRA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SABRA HEALTH CARE REIT INC (SBRA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to SBRA.


Can you provide the valuation status for SABRA HEALTH CARE REIT INC?

ChartMill assigns a valuation rating of 2 / 10 to SABRA HEALTH CARE REIT INC (SBRA). This can be considered as Overvalued.


Can you provide the profitability details for SABRA HEALTH CARE REIT INC?

SABRA HEALTH CARE REIT INC (SBRA) has a profitability rating of 5 / 10.


What are the PE and PB ratios of SABRA HEALTH CARE REIT INC (SBRA) stock?

The Price/Earnings (PE) ratio for SABRA HEALTH CARE REIT INC (SBRA) is 31.32 and the Price/Book (PB) ratio is 1.79.


How financially healthy is SABRA HEALTH CARE REIT INC?

The financial health rating of SABRA HEALTH CARE REIT INC (SBRA) is 3 / 10.